SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bodey GP,Buckley M,Sathe YS,Freireich EJ. Quantitative Relationships Between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med. 1966; 64: 328340.
  • 2
    Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents. 2000; 16: 107111.
  • 3
    Hughes WT,Armstrong D,Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730751.
  • 4
    Orudjev E,Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol. 2002; 39: 7785.
  • 5
    Rackoff WR,Gonin R,Robinson C,Kreissman SG,Breitfeld PP. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol. 1996; 14: 919924.
  • 6
    Santolaya ME,Alvarez AM,Becker J, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol. 2001; 19: 34153421.
  • 7
    Paganini H,Bologna R,Debbag R., et al. Neutropenia and fever in child in one single institution in Argentina. Pediatr Hematol Oncol. 1998; 15: 405413.
  • 8
    Talcott JA,Finberg R,Mayer RJ,Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988; 148: 25612568.
  • 9
    Talcott JA,Siegel RD,Finberg R,Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316322.
  • 10
    Guiguet M,Blot F,Escudier B,Antoun S,Leclercq B,Nitemberg G. Severity-illness cores for neutropenic cancer patients in an intensive care unit: which is the best predictor? Do multiple assessment times improve the predictive value? Crit Care Med. 1998; 26: 488493.
  • 11
    Heying R,Scheneider DT,Korholz D,Stannigel H,Lembyrg P,Gobel U. Efficacy and outcome of intensive care in pediatric oncologic patients. Crit Care Med. 2001; 29: 22762280.
  • 12
    Blot F,Cordonier C,Buzin A, et al. Severity of illness scores: are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study. Crit Care Med. 2001; 29: 21252131.
  • 13
    Klastersky J,Paesmans M,Rubenstein RB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18: 30383051.
  • 14
    Paganini HR,Sarkis CM,De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer. 2000; 88: 28482852.
  • 15
    Shenep JL,Flynn PM,Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis. 2001; 32: 3643.
  • 16
    Paganini H,Rodriguez Brieshcke T,Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. A randomized controlled trial. Cancer. 2001; 91: 15631567.
  • 17
    Kern WV,Cometta A,DeBock R,Langenaeken J,Paesmans M,Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy.International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999; 341: 312318.
  • 18
    Mullen CA,Petropoulos D,Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999; 86: 126134.
  • 19
    Papadimitris C,Dimopoulos MA,Kostis E, et al. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Oncology. 1999; 57: 127130.
  • 20
    Malik IA,Khan WA,Karim M,Aziz Z,Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med. 1995, 98: 224231.
  • 21
    Talcott JA,Whalen A,Clark J,Rieker PP,Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on validated prediction rule. J Clin Oncol. 1994; 12: 107114.
  • 22
    Paganini H,Gomez S,Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease. Cancer. 2003; 97: 17751780.
  • 23
    Saez-Llorens X,McCracken GH. Sepsis syndrome and septic shock in pediatrics: current terminology, pathophysiology, and management. J Pediatr. 1993; 123: 497508.
  • 24
    Lacy CF,Armstrong LL,Goldman MP,Lance LL. Drug Information Handbook, 7th ed. Hudson, Ohio: Lexi-Comp Inc.; 1999.
  • 25
    Santolaya ME,Alvarez AM,Aviles CL, et al. Early discharge followed by outpatient managment versus continued hospitalization of children with cancer, fever, and neutropenia at low risk invasive bacterial infection. J Clin Oncol. 2004; 22: 37843789.
  • 26
    Rolston KVI. New trends in patients management: risk-based therapy for febrile patients with neutropenia. Cancer. 1999; 85: 213219.
  • 27
    Freifeld A,Marchigiani D,Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999; 341: 305311.
  • 28
    Jones GR,Konsler GK,Dunaway RP,Pusek SN. Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol. 1996; 13: 217229.
  • 29
    Baorto EP,Aquino VM,Mullen CA,Buchanan GR,DeBaun MR. Clinical parameters associated with low bacteriemia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer. 2001; 92: 909913.